Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.
2.

The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.

Jackson MJ, Andree TH, Hansard M, Hoffman DC, Hurtt MR, Kehne JH, Pitler TA, Smith LA, Stack G, Jenner P.

J Neural Transm (Vienna). 2010 Jan;117(1):55-67. doi: 10.1007/s00702-009-0323-9. Epub 2009 Oct 7.

PMID:
19809864
3.

GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.

Iravani MM, Costa S, Jackson MJ, Tel BC, Cannizzaro C, Pearce RK, Jenner P.

Eur J Neurosci. 2001 Feb;13(3):597-608.

PMID:
11168568
4.

The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.

Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.

Eur J Pharmacol. 2006 Sep 28;546(1-3):82-7. Epub 2006 Jul 25.

PMID:
16925991
5.

L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.

Ando K, Inoue T, Itoh T.

Pharmacol Biochem Behav. 2014 Dec;127:62-9. doi: 10.1016/j.pbb.2014.10.009. Epub 2014 Oct 31.

PMID:
25449794
6.

Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.

Pearce RK, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD.

Psychopharmacology (Berl). 1999 Feb;142(1):51-60.

PMID:
10102782
7.
8.
9.

The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.

Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P.

Exp Neurol. 2010 Dec;226(2):320-7. doi: 10.1016/j.expneurol.2010.09.007. Epub 2010 Sep 16.

PMID:
20843474
10.
12.

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.

Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P.

Mov Disord. 2005 Mar;20(3):306-14.

PMID:
15490461
13.

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.

Pearce RK, Banerji T, Jenner P, Marsden CD.

Mov Disord. 1998 Mar;13(2):234-41.

PMID:
9539335
14.

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

Maratos EC, Jackson MJ, Pearce RK, Cannizzaro C, Jenner P.

Exp Neurol. 2003 Jan;179(1):90-102.

PMID:
12504871
15.

Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.

Stockwell KA, Scheller D, Rose S, Jackson MJ, Tayarani-Binazir K, Iravani MM, Smith LA, Olanow CW, Jenner P.

Exp Neurol. 2009 Oct;219(2):533-42. doi: 10.1016/j.expneurol.2009.07.011. Epub 2009 Jul 18.

PMID:
19619533
16.
17.

The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.

Zubair M, Jackson MJ, Tayarani-Binazir K, Stockwell KA, Smith LA, Rose S, Olanow W, Jenner P.

Exp Neurol. 2007 Dec;208(2):177-84. Epub 2007 May 8.

PMID:
17935716
18.

The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.

Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T.

Eur J Pharmacol. 2015 Nov 5;766:25-30. doi: 10.1016/j.ejphar.2015.09.028. Epub 2015 Sep 28.

PMID:
26415982
19.
20.

Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.

Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.

Mov Disord. 2002 Sep;17(5):887-901.

PMID:
12360537

Supplemental Content

Support Center